98 results
6-K
EX-99.2
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
safety profile. Most treatment emergent adverse events (TEAEs) were Grade 1 or 2 and the majority of the few Grade 3 events were hematological … 2023): GLPG5101 showed an encouraging safety profile with most TEAEs of Grade 1 or 2; the majority of Grade 3 events were hematological. No CRS Grade
6-K
EX-99.15
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
and the U.S., with the majority of our competitors based in the U.S. The peer groups consist of publicly listed biotechnology and pharmaceutical
6-K
EX-99.3
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
and voting on the agenda items referred to in the aforementioned agenda of the Annual Shareholders’ Meeting.
Voting and majority: Subject … agenda of the Annual Shareholders’ Meeting shall be passed if they are approved by a simple majority of the votes validly cast by the shareholders.
2
6-K
EX-99.9
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
67,022,402.04 (excluding issue premium). The aforementioned authorization can be used by the Board of Directors by a simple majority resolution for capital
6-K
EX-99.1
0lonk 0yo
12 Dec 23
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
7:02am
S-8
EX-99.2
hdkn1tri1ao8pivx rz
4 Dec 23
Registration of securities for employees
5:16pm
S-8
EX-99.3
3wrn1c4 soa
4 Dec 23
Registration of securities for employees
5:16pm
S-8
EX-4.1
2p38gniq0vp1 5ryh0vx
4 Dec 23
Registration of securities for employees
5:16pm
S-8
EX-99.1
c1is7l8x
4 Dec 23
Registration of securities for employees
5:16pm
6-K
EX-99.1
4jaqzi
12 Jun 23
Current report (foreign)
7:32am
6-K
EX-99.1
el3a40nx6 chnrv1e
13 Dec 22
Galapagos and CellPoint presented encouraging initial data at ASH 2022 for GLPG5101, a CD19 CAR-T candidate manufactured at point-of-care
7:49am
S-8
EX-99.2
0n567wney0xf2n63r
12 Dec 22
Registration of securities for employees
4:08pm
S-8
EX-4.1
dgp2rt
12 Dec 22
Registration of securities for employees
4:08pm
S-8
EX-99.3
ir2yb3852h7cmp95d
12 Dec 22
Registration of securities for employees
4:08pm